Η NVS έλαβε τη θετική γνωμοδότηση της CHMP για τον πρώτο αναστολέα της IL-17A Σεκουκινουμάμπη
- Η Σεκουκινουμάμπη προτείνεται για έγκριση στην Ευρώπη για την θεραπευτική αντιμετώπιση ασθενών με αγκυλοποιητική σπονδυλοαρθρίτιδα (ΑΣ) και ψωριασική αρθρίτιδα (ΨΑ)
- Η Σεκουκινουμάμπη εμφάνισε ταχεία έναρξη δράσης και μακροπρόθεσμη διατήρηση της αποτελεσματικότητας σε ασθενείς με ή χωρίς προηγούμενη θεραπεία με αναστολέα του παράγοντα νέκρωσης όγκων (αντι-TNF)1,2
- Υπάρχει επείγουσα ανάγκη για νέα φάρμακα, καθώς σημαντικός αριθμός ασθενών με ΑΣ και ΨΑ δεν είναι ικανοποιημένοι από τις τρέχουσες θεραπείες3-6
Σχετικά με την σύσταση της CHMP
Σχετικά με την αγκυλοποιητική σπονδυλοαρθρίτιδα (ΑΣ)
Σχετικά με τη Σεκουκινουμάμπη και την ιντερλευκίνη 17A (IL-17A)
Δήλωση αποποίησης ευθύνης
Βιβλιογραφία:
-
Sieper J, Braun J, Baraliakos X, et al. Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a phase 3, randomized, placebocontrolled trial with subcutaneous loading and maintenance dosing. ACR/ARHP Annual Meeting, Boston, MA, USA, 2014. Poster presentation (presentation number 536).
-
Mease, PJ, McInnes, IB, Kirkham, B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2015; 386, No. 9999; p1137–1146.
-
Dougados M, Baeten D. Spondyloarthritis. The Lancet. 2011;377-2127-37.
-
Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4-12.
-
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137-74.
-
Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53(4):650-7.
-
Armstrong AW, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013 Oct;149(10):1180-5.
-
United Nations. World Population Prospects - The 2012 Revision. Last accessed October 2015 at http://esa.un.org/unpd/wpp/Publications/Files/WPP2012_Volume-I_Comprehen....
-
Lai-Shan Tam, Ying-Ying Leung and Edmund K. Li. Psoriatic arthritis in Asia. Last accessed October 2015 at http://rheumatology.oxfordjournals.org/content/early/2009/08/27/rheumato....
-
Novartis data on file, September 2015.
-
Baeten D, Braun J, Baraliakos X, et al. Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52-week phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosing. ACR /ARHP Annual
-
Meeting, Boston, MA, USA, 2014. Oral presentation (Abstract number 819).
-
Mease, PJ, McInnes, IB, Kirkham, B, et al. Secukinumab Inhibition of Interleukin-17A in Patients With Psoriatic Arthritis. N Engl J Med. 2015; 373(14):1329-39.
-
Barkham N, Kong K O, Tennant A, et al. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology. 2005; 44:1277–1281.
-
Feldtkeller E, Khan M, Van Der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. Positive patients with ankylosing spondylitis. Rheum Int. 2003;23(2):61-66.
-
National Psoriasis Foundation. Press release: Nearly one in four people with psoriasis may have undiagnosed psoriatic arthritis according to a recent study from the National Psoriasis Foundation. Last accessed October 2015 at https://www.psoriasis.org/page.aspx?pid=2197.
-
Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014; 141:133-42.
-
Gaffen SL. Structure and signaling in the IL-17 receptor family. Nat Rev Immunol. 2009;9(8):556-67.
-
Ivanov S, Linden A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci. 2009;30(2):95- 103.
-
Kopf M, Bachmann MF, Marsland BJ. Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov. 2010; 9(9):703-18.
-
Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129(3):311-21.
-
Krueger J, Fretzin S, Suárez-Fariñas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145-154.
-
Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Brit J Dermatol. 2009;160(2):319-24.